2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Neelima Denduluri, MD, medical oncologist, Virginia Cancer Specialists, discusses the role of neoadjuvant therapy in HER2-positive breast cancer and triple-negative breast cancer.
Neelima Denduluri, MD, medical oncologist, Virginia Cancer Specialists, discusses the role of neoadjuvant therapy in HER2-positive breast cancer and triple-negative breast cancer.
Historically, once a patient’s tumor has been surgically removed, they go on to receive adjuvant therapy to minimize their risk of recurrence. Over the past five years, research has shown thatneoadjuvant therapy can reduce a patient’s disease burden and can be given in the form of HER2-directed therapy, endocrine therapy, or chemotherapy. Notably, a patient who has a favorable response to neoadjuvant therapy often has a better overall outcome, says Denduluri.
Ultimately, if a patient has high-risk disease, they should be considered for neoadjuvant therapy, advises Denduluri.
Related Content: